Results 271 to 280 of about 99,788 (345)

Cutaneous Malignant Melanoma

open access: yesActa Oncologica Turcica, 2014
openaire   +1 more source

Fenofibrate potentiates the therapeutic efficacy of EZH2 inhibitors on melanoma via TRIM21‐ and OTUD4‐mediated EZH2 ubiquitination

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 11, Page 2675-2694, June 2026.
Background and Purpose EZH2 (enhancer of zeste homologue 2) inhibitors are an emerging class of drugs that target epigenetic regulation. However, their efficacy in solid tumours has been limited, partly due to drug‐induced upregulation of fatty acid synthesis.
Rui Cheng   +10 more
wiley   +1 more source

Desmoplastic Cutaneous Squamous Cell Carcinoma Is an Aggressive and Potentially Fatal Skin Cancer: A Systematic Review

open access: yesJournal of Cutaneous Pathology, Volume 53, Issue 6, Page 551-561, June 2026.
ABSTRACT The incidence and mortality of cutaneous squamous cell carcinoma (cSCC) are increasing. Desmoplastic cSCC (dcSCC) is an uncommon yet highly aggressive variant which has received relatively little attention in the literature. No systematic reviews of dcSCC are currently available.
Andrew Dettrick   +6 more
wiley   +1 more source

The Impact of Clinical and Dermoscopic Photographs on the Diagnostic Accuracy of Remote Optical Coherence Tomography Assessment for Basal Cell Carcinoma Detection: A Comparative Diagnostic Study

open access: yesInternational Journal of Dermatology, Volume 65, Issue 6, Page 1231-1237, June 2026.
ABSTRACT Background Remote assessment of optical coherence tomography (OCT) scans for basal cell carcinoma (BCC) detection enhances access to OCT‐guided dermatologic care, but prohibits direct lesion inspection. The value of clinical and dermoscopic photographs when remotely assessing OCT scans remains unknown.
Tom Wolswijk   +7 more
wiley   +1 more source

Comparison of Morbidity Between Sentinel Lymph Node Biopsy and Elective Neck Dissection in Dogs With Head and Neck Malignancies

open access: yesVeterinary and Comparative Oncology, Volume 24, Issue 2, Page 313-323, June 2026.
ABSTRACT Elective neck dissection (END) and sentinel lymph node biopsy (SLNB) are suggested for nodal staging of canine head and neck malignancies (HNM). This study aims to compare the morbidity of END to SLNB. Seventy‐six client‐owned dogs with HNM that underwent END (n = 28) or SLNB (n = 48) in two institutions were retrospectively enrolled ...
Lavinia Elena Chiti   +7 more
wiley   +1 more source

Epidemiology of Four Major Canine Tumours in the UK: Insights From a National Pathology Registry With Comparative Oncology Perspectives

open access: yesVeterinary and Comparative Oncology, Volume 24, Issue 2, Page 324-340, June 2026.
ABSTRACT Pet dogs with naturally occurring cancers provide valuable models for comparative oncology and pathology tumour registries offer a powerful resource for onco‐epidemiological research. Here, we analysed the Small Animal Veterinary Surveillance Network (SAVSNET) pathology‐based tumour registry (PTR), one of the largest veterinary tumour ...
José Rodríguez   +9 more
wiley   +1 more source

CD30 Expression in Neoplastic Mast Cells and the Presence of CD30+, CD3+, and PAX‐5+ Tumour‐Infiltrating Lymphocytes as Prognostic Markers in Canine Cutaneous Mast Cell Tumours

open access: yesVeterinary and Comparative Oncology, Volume 24, Issue 2, Page 341-352, June 2026.
ABSTRACT Canine cutaneous mast cell tumour (MCT) is the most common skin neoplasm in dogs, with histopathology serving as both the diagnostic and primary prognostic tool. However, identifying reliable biomarkers is essential for improving clinical decision‐making.
Fernanda Ramalho Ramos   +6 more
wiley   +1 more source

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real‐world study

open access: yesCancer, Volume 132, Issue 10, 15 May 2026.
Momelotinib demonstrated robust real‐world activity after ruxolitinib failure, with clinically meaningful improvements in spleen (≥50% spleen length reduction, 30.0%), symptoms (≥50% total symptoms score reduction, 39.2%), and anemia (major response, 35.7%) at 6 months.
Francesca Palandri   +41 more
wiley   +1 more source

Home - About - Disclaimer - Privacy